MarketYZG-331
Company Profile

YZG-331

YZG-331, also known as N6-[(S)-1-(phenyl)propyl]adenosine, is an adenosine receptor agonist which is or was under investigation for the potential treatment of insomnia.

Pharmacology
The drug appears to act through the adenosine A1 and A2A receptors. == Development ==
Development
YZG-331 was first described in the scientific literature by at least 2014. As of 2025, it has reached the preclinical research stage of development. == See also ==
tickerdossier.comtickerdossier.substack.com